Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nalu-0012
- Development stage
- Preclinical
- Lead developer
- Nalu Bio
- Modality
- Small Molecules
01
Overview
Nalu-0012 is a small molecule drug candidate being developed by Nalu Bio for the treatment of metabolic and immune-related disorders. Currently in the basic research stage, the compound is designed to modulate G protein-coupled receptors (GPCRs) within the endocannabinoid system (ECS). Nalu Bio's platform focuses on the development of high-purity, chemically synthesized cannabinoids and ECS-targeted molecules to provide precision therapeutic effects while avoiding the impurities and variability associated with hemp-derived products. The specific GPCR targets and the exact functional effect (e.g., agonism or antagonism) of Nalu-0012 have not been publicly disclosed.
Beyond the preview
Go deeper on Nalu-0012.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nalu-0012.